-
The new version of the medical insurance catalog is implemented today!
Time of Update: 2021-03-23
On December 28, the results of the 2020 medical insurance negotiations were announced.
A total of 162 drugs were negotiated and 119 negotiations were successful.
-
Orphan drug research and development progress 5 pictures in seconds
Time of Update: 2021-03-23
Because of the small number of patients with rare diseases, low market demand, and high research and development costs, companies are not very enthusiastic about developing orphan drugs, but because all countries have introduced them A series of encouraging policies have been adopted.
-
Implementation of the new version of the medical insurance catalogue, 119 national talks officially reduced the price of drugs
Time of Update: 2021-03-23
Tilelizumab: For example, BeiGene's star product tislelizumab (BaiZian), the indication for entering the medical insurance this time is the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line chemotherapy; PD- The failure of platinum-containing chemotherapy with high L1 expression includes the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy.
-
The State Drug Administration issued a document: 226 drugs written off
Time of Update: 2021-03-23
Low drug prices make pharmaceutical companies withdraw from the market The drugs with the highest number of cancellations this time are acetaminophen tablets and captopril tablets, and seven approvals have been cancelled respectively.
-
Drug Administration: Catalog of Generic Drug Ginseng Preparations (39th Batch)
Time of Update: 2021-03-23
35 34，，（）。 。 ：（） 76%; height: 30px"> 42%; height: 30px"> 06%; height: 30px"> / 96%; height: 30px"> 3%; height: 30px"> 4%; height: 30px"> 1 06%; height: 30px"> 2 76%; height: 30px"
-
Background interpretation of the current round of revision of the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-03-23
34 ，。200014《》（《》），《》、、、。，，20142017、、。 20201221，《（）》（《》）。《》、、。 《》，： ：，、 20，800025000，，。 2014， 20%，。15%，。 2020，，，。，。，。。 ：， 2017“”《》，、、，。 1. 。201712，《（）》，，，。20198，《》，、、、、、、。，，，。 《》，、、、、；、、。 2
-
The local government was investigated for monopolizing the purchasing power of consumables and pharmaceutical equipment distribution!
Time of Update: 2021-03-23
Strengthen anti-monopoly law enforcement Focus on the fields of medicine, bidding and government procurement When it comes to preventing the abuse of administrative power to restrict competition, I have to talk about the recent comprehensive clean-up of regulations and practices that hinder the unified market and fair competition in the Guangdong-Hong Kong-Macao Greater Bay Area.
-
Sichuan: These consumables are included in centralized procurement to encourage medical institutions to negotiate prices independently
Time of Update: 2021-03-23
cn/news/yyzb/" target="_blank"> procurement procurement It is worth noting that in terms of procurement methods, the above interpretation shows that the province's pharmaceutical institutions are encouraged to negotiate and purchase independently with pharmaceutical companies below the linkage reference price.
-
National Health And Wellness Commission: Public hospital visits fell by 13%!
Time of Update: 2021-03-23
6%，、。、，。 1146 new private hospitals were added , Clinic becomes the only growth institution in primary care Statistics show that as of the end of November 2020, the number of medical and health institutions nationwide has reached 1.
-
German Merck obtains exclusive global development rights for xevinapant
Time of Update: 2021-03-23
Currently in the pivotal Phase 3 TrilynX study, a combination of platinum-containing chemotherapy and standard fractionation intensity-modulated radiotherapy (standard fractionation intensity-modulated radiotherapy) for previously untreated patients with high-risk locally advanced head and neck squamous cell carcinoma (LA SCCHN) .
-
The Health Commission clearly replied: the establishment of public hospitals will be strengthened!
Time of Update: 2021-03-23
The response stated that the establishment of public hospitals is a key element for stabilizing and attracting medical staff, ensuring the stable development of public hospitals, and an important system guarantee for the country to meet the needs of the people for medical and health services.
-
Puli Pharmaceuticals: Bivarudin for injection successfully challenged the US patent
Time of Update: 2021-03-23
On March 2, Puli Pharmaceuticals announced that the company obtained the FDA's provisional approval for bivalerudin for injection in December 2020, and in January 2021, it will issue a marketing license and patent holder for the original formulation of the product.
-
"Hometown of Medicinal Materials" Bozhou, the price of traditional Chinese medicinal materials has generally risen after the fourth quarter of last year
Time of Update: 2021-03-23
There are 128 varieties of Chinese medicinal materials whose prices will increase in January 2021.
-
Sihuan Biological Director Huang Xi resigns
Time of Update: 2021-03-23
Huang Xi, who applied for resignation from the company’s 9th board of directors due to personal reasons.
Huang Xi ceased to hold any position in the company.
Huang Xi does not hold the company's stock.
-
Saisheng Pharmaceutical is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-03-23
In the previous public offering, the initial offer shares offered by Saisheng Pharmaceutical have been moderately over-subscribed, which is equivalent to approximately 1,068.
05 times the 11,599,000 Hong Kong offer shares initially available for subscription under the Hong Kong Public Offering.
-
In February 2021, the world's first batch of 7 new drugs, the fourth CAR-T therapy Breyanzi was approved by the FDA
Time of Update: 2021-03-23
Author: SeaAccording to the global drug database of Yaodu, in February 2021, there were 7 new drugs approved for marketing for the first time in the world, all of which were approved by the FDA. Amon
-
8 new drugs approved by the FDA in February 2021
Time of Update: 2021-03-23
Tepmetko (Tepotinib)On February 3, the FDA approved the MET inhibitor tepotinib (trade name: TEPMETKO) developed by EMD Serono, a subsidiary of Merck, Germany through a priority review method for the treatment of jumping mutations in exon 14 (MET ex14) of the MET gene.
-
80 new drugs explode the 400 billion Chinese patent medicine market!
Time of Update: 2021-03-23
80 new Chinese patent medicines are on the market: the number of gynecology is the largest, and the pediatrics has a big surprise According to data from Mi Nei. com, in 2019, the total market size of Chinese patent medicines in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminals and China's urban entity pharmacies terminals has approached 400 billion yuan.
-
A battle for people! Those flowing CMO (Chief Medical Officer).
Time of Update: 2021-03-23
He has served as the chief medical officer of Zai Lab, and successively worked in Qilu Pharmaceutical, Ambrx, Amgen, Amgen China, Novartis, Roche and other multinational companies hold important positions and have been responsible for multiple project development and product listings.
-
Chinese traditional medicine Huashibaidu Granules approved for listing
Time of Update: 2021-03-23
On March 3, China Traditional Chinese Medicine announced on the Hong Kong Stock Exchange that the State Food and Drug Administration approved the Guangdong Party’s Huashibaidu Granules to be listed in an emergency through a special approval procedure.
drug.
